Geli\u015fen onkoloji d\u00fcnyas\u0131nda, kanser tan\u0131 ve tedavisine y\u00f6nelik yeni nesil molek\u00fcler hedeflerin ke\u015ffi, hasta y\u00f6netiminde devrim niteli\u011finde ad\u0131mlar\u0131n at\u0131lmas\u0131n\u0131 sa\u011fl\u0131yor. Nisan 2025\u2019te Journal of Nuclear Medicine\u2019da yay\u0131mlanan \u00f6nc\u00fc bir \u00e7al\u0131\u015fma, agresif kat\u0131 t\u00fcm\u00f6rlerde belirgin \u015fekilde a\u015f\u0131r\u0131 eksprese edilen IL13R\u03b12 adl\u0131 antijen \u00fczerinde y\u00fcksek \u00f6zg\u00fcll\u00fc\u011fe sahip, radyoaktif i\u015faretlenmi\u015f yenilik\u00e7i bir antikor geli\u015ftirilerek bu alanda \u00e7\u0131\u011f\u0131r a\u00e7t\u0131. KLG-3 olarak adland\u0131r\u0131lan bu molek\u00fcl, \u00f6zellikle glioblastom, melanom ve \u00fc\u00e7l\u00fc negatif meme kanseri gibi y\u00fcksek agresifli\u011fe sahip t\u00fcm\u00f6rlerdeki IL13R\u03b12 pozitif h\u00fccreleri ba\u015far\u0131yla hedeflerken, yak\u0131n akraba resept\u00f6r olan IL13R\u03b11\u2019e neredeyse hi\u00e7 ba\u011flanmamas\u0131yla yan etkilerin minimize edilebilece\u011fi yeni bir d\u00f6nemin kap\u0131s\u0131n\u0131 aral\u0131yor.<\/p>\n
\u0130nterl\u00f6kin-13 resept\u00f6r alfa-2 (IL13R\u03b12), uzun s\u00fcredir onkolojik biyobelirte\u00e7ler aras\u0131nda \u00f6ne \u00e7\u0131k\u0131yor. Bunun sebebi, IL13R\u03b12\u2019nin sa\u011fl\u0131kl\u0131 dokularda s\u0131n\u0131rland\u0131r\u0131lm\u0131\u015f ekspresyonu ancak pek \u00e7ok agresif kat\u0131 t\u00fcm\u00f6rde y\u00fcksek seviyelerde bulunmas\u0131d\u0131r. Bu \u00f6zg\u00fcn ifade profili, IL13R\u03b12\u2019yi hem tan\u0131 koymada hem de hedefe y\u00f6nelik terapilerde ideal bir hedef olarak \u00f6n plana \u00e7\u0131karmaktad\u0131r. Ancak t\u00fcm bu avantajlar\u0131na ra\u011fmen, hen\u00fcz klinik ortamda IL13R\u03b12\u2019ye y\u00f6nelik antikor bazl\u0131 tedavi ya da tan\u0131 y\u00f6ntemleri yayg\u0131nla\u015fmam\u0131\u015ft\u0131. Bahsi ge\u00e7en \u00e7al\u0131\u015fma, bu eksikli\u011fi hedefleyerek preklinik evrede \u00e7arp\u0131c\u0131 sonu\u00e7lar ortaya koyuyor.<\/p>\n
Ara\u015ft\u0131rma grubu, Houston\u2019daki MD Anderson Kanser Merkezi\u2019nden Dr. Simone Krebs liderli\u011finde, Memorial Sloan Kettering Kanser Merkezi\u2019nde y\u00fcr\u00fct\u00fclen ortak \u00e7al\u0131\u015fmalarla, IL13R\u03b12\u2019ye \u00f6zg\u00fc be\u015f farkl\u0131 insan antikorunu (KLG-1\u2019den KLG-5\u2019e kadar) ba\u015far\u0131yla sentezledi. Bu antikorlar\u0131n hepsi, IL13R\u03b12\u2019ye ba\u011flanma \u00f6zellikleri a\u00e7\u0131s\u0131ndan detayl\u0131 laboratuvar analizlerinden ge\u00e7irildi. Ba\u011flanma afinitesi, \u00f6zg\u00fcll\u00fck ve IL13R\u03b11 ile kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7apraz reaksiyon gibi parametrelerde yap\u0131lan testler sonucunda, KLG-3 \u00f6ne \u00e7\u0131karak y\u00fcksek ba\u011flanma kineti\u011fi ve kusursuz \u00f6zg\u00fcll\u00fc\u011f\u00fcyle birincil aday olarak belirlendi. Bu seviyede \u00f6zg\u00fcll\u00fck, klasik imm\u00fcn g\u00f6r\u00fcnt\u00fclemede yanl\u0131\u015f pozitifliklerin \u00f6n\u00fcne ge\u00e7ilmesinde kritik \u00f6nem ta\u015f\u0131yor.<\/p>\n
KLG-3\u2019\u00fcn in vivo performans\u0131 ise immuno-pozitron emisyon tomografisi (immuno-PET) ile glioblastom fare modellerinde test edildi. Zirconium-89 (^89Zr) radyoizotopu ile i\u015faretlenen KLG-3, enjeksiyondan 144 saat sonra ger\u00e7ekle\u015ftirilen PET\/BT g\u00f6r\u00fcnt\u00fclemede t\u00fcm\u00f6rde yo\u011fun tutulum sergiledi. Ayn\u0131 zamanda, hedef d\u0131\u015f\u0131 organlarda minimal radyoaktifikik birikimi g\u00f6zlemlendi. B\u00f6ylece, y\u00fcksek t\u00fcm\u00f6r\/normal doku oran\u0131 ile KLG-3\u2019\u00fcn hem t\u00fcm\u00f6r s\u0131n\u0131rlar\u0131n\u0131n net bi\u00e7imde ortaya konmas\u0131 hem de t\u00fcm\u00f6r y\u00fck\u00fcn\u00fcn do\u011fru takibi a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck potansiyel sundu\u011fu ortaya \u00e7\u0131kt\u0131.<\/p>\n
Klinik uygulama \u00f6ncesi uygulama dozu optimizasyonu i\u00e7in yap\u0131lan kitle doz titrasyon \u00e7al\u0131\u015fmas\u0131, d\u00fc\u015f\u00fck dozlarda bile g\u00fc\u00e7l\u00fc sinyal yo\u011funlu\u011fu elde edilebilece\u011fini g\u00f6sterdi. Bu durum, sistemik antikor maruziyetinin azalt\u0131lmas\u0131 ve b\u00f6ylece hastalarda olu\u015fabilecek olas\u0131 yan etkilerin en aza indirilmesi a\u00e7\u0131s\u0131ndan son derece \u00f6nemli bir avantaj sa\u011fl\u0131yor. \u00c7al\u0131\u015fman\u0131n tamamlay\u0131c\u0131 aya\u011f\u0131 olarak yap\u0131lan eks vivo biyodistrib\u00fcsyon testleri ise KLG-3\u2019\u00fcn dokular aras\u0131nda da\u011f\u0131l\u0131m ve eliminasyonunu ayr\u0131nt\u0131l\u0131 \u015fekilde ortaya koyarak, radyoaktif terap\u00f6tik versiyonu olan lutetium-177 (^177Lu) konjugasyonu i\u00e7in dozimetri hesaplar\u0131n\u0131n g\u00fcvenilir bi\u00e7imde yap\u0131lmas\u0131na olanak tan\u0131d\u0131.<\/p>\n
KLG-3 ile yap\u0131lan t\u00fcm bu \u00e7al\u0131\u015fmalar sadece glioblastom ile s\u0131n\u0131rl\u0131 kalmad\u0131; antikor ayn\u0131 zamanda melanom modellerinde de test edilerek benzer etkinlik ve uygun farmakokinetik \u00f6zellikler g\u00f6sterdi. Bu da KLG-3\u2019\u00fcn sadece tek bir t\u00fcm\u00f6r t\u00fcr\u00fcne de\u011fil, IL13R\u03b12\u2019nin y\u00fcksek oldu\u011fu pek \u00e7ok agresif kanser t\u00fcr\u00fcne y\u00f6nelik \u00e7ok ama\u00e7l\u0131, geni\u015f spektrumlu kullan\u0131labilirli\u011finin habercisi oldu. Bu bariz \u00e7ok y\u00f6nl\u00fcl\u00fck, KLG-3 antikor platformunun gelecekte \u00e7e\u015fitli malignitelerde kullan\u0131labilecek evrensel bir molek\u00fcl haline d\u00f6n\u00fc\u015fmesini m\u00fcmk\u00fcn k\u0131l\u0131yor.<\/p>\n
Dozimetri analizleri, ^177Lu ile konjuge edilen KLG-3\u2019\u00fcn d\u00fc\u015f\u00fck radyoaktif aktivitelerle bile t\u00fcm\u00f6rlerde etkili radyasyon dozu sa\u011flayabilece\u011fini ortaya koydu. B\u00f6ylece, terap\u00f6tik indeks artarken tedaviye ba\u011fl\u0131 yan etkilerin azalabilece\u011fi \u00f6ng\u00f6r\u00fcl\u00fcyor. KLG-3, \u00e7ift fonksiyonlu bir molek\u00fcl olarak hem y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc tan\u0131 imkan\u0131 sunan immuno-PET ajan\u0131 hem de hedefe \u00f6zg\u00fc radyoimmunoterapi arac\u0131 olarak onkolojide tedavi ve tan\u0131n\u0131n b\u00fct\u00fcnle\u015fmesini sa\u011flama potansiyeli ta\u015f\u0131yor.<\/p>\n
\u0130lgin\u00e7 bir \u015fekilde IL13R\u03b12, sadece t\u00fcm\u00f6r h\u00fccrelerine \u00f6zg\u00fc bir hedef olman\u0131n \u00f6tesinde, t\u00fcm\u00f6r mikro\u00e7evresinde imm\u00fcnosupresyonun \u015fekillenmesinde de rol oynuyor. KLG-3 tabanl\u0131 immuno-PET ile IL13R\u03b12 ekspresyonunun tespiti, imm\u00fcnosupresif fenotip g\u00f6steren hastalar\u0131n belirlenmesini sa\u011flayabilir ve buna ba\u011fl\u0131 olarak ba\u011f\u0131\u015f\u0131kl\u0131k sistemi mod\u00fclasyonunu i\u00e7eren kombine tedavi stratejilerinin ki\u015fiselle\u015ftirilmesine destek olabilir. Bu, hem tan\u0131 hem de tedavi planlamas\u0131nda kapsaml\u0131 bir yakla\u015f\u0131m\u0131n olu\u015fmas\u0131na imkan tan\u0131yor.<\/p>\n
MD Anderson, Memorial Sloan Kettering Kanser Merkezi ve Tri-Institutional Therapeutics Discovery Institute gibi \u00f6nde gelen ara\u015ft\u0131rma kurumlar\u0131n\u0131n bir araya gelerek y\u00fcr\u00fctt\u00fc\u011f\u00fc bu multidisipliner \u00e7al\u0131\u015fma, molek\u00fcler biyoloji, n\u00fckleer t\u0131p ve onkoloji alanlar\u0131n\u0131n kusursuz entegrasyonunu g\u00f6zler \u00f6n\u00fcne seriyor. Bu t\u00fcr g\u00fc\u00e7l\u00fc i\u015f birlikleri, yeni molek\u00fcllerin \u201cbench to bedside\u201d yani laboratuvardan klinik kullan\u0131m a\u015famas\u0131na ta\u015f\u0131nmas\u0131nda kritik rol oynuyor.<\/p>\n
KLG-3\u2019\u00fcn sundu\u011fu avantajlar, onkoloji prati\u011finde derin yank\u0131lar uyand\u0131racak nitelikte. PET tabanl\u0131 y\u00fcksek \u00f6zg\u00fcll\u00fckte t\u00fcm\u00f6r g\u00f6r\u00fcnt\u00fcleme imkan\u0131 ve hedefe y\u00f6nelik radyoaktif tedavi y\u00f6ntemlerinin birle\u015fmesi, kanser tan\u0131 ve tedavisinde hem etkinli\u011fi art\u0131r\u0131yor hem de toksisiteyi azalt\u0131yor. Bu da hastalar\u0131n ya\u015fam kalitesinde g\u00f6zle g\u00f6r\u00fcl\u00fcr iyile\u015fme anlam\u0131na geliyor. Yak\u0131n gelecekte yap\u0131lacak klinik \u00e7al\u0131\u015fmalar, KLG-3\u2019\u00fcn insanlarda etkinlik ve g\u00fcvenilirli\u011fini net olarak belirleyecek ve molek\u00fcl\u00fcn rutin klinik prati\u011fe giri\u015f yolunu a\u00e7acak.<\/p>\n
Bununla birlikte, bu ara\u015ft\u0131rma sadece terap\u00f6tik ve tan\u0131sal bir ara\u00e7 geli\u015ftirmekle kalm\u0131yor; ayn\u0131 zamanda IL13R\u03b12 zengin t\u00fcm\u00f6r biyolojisinin ve imm\u00fcnolojik ortam\u0131n\u0131n daha derin anla\u015f\u0131lmas\u0131na katk\u0131 sa\u011fl\u0131yor. KLG-3 ve benzeri antikorlar, sadece tedavide de\u011fil, ayn\u0131 zamanda t\u00fcm\u00f6r\u00fcn molek\u00fcler evrimi, tedaviye yan\u0131t ve hastal\u0131k izleminde de vazge\u00e7ilmez birer ara\u00e7 haline gelebilir. Bu, ki\u015fiye \u00f6zel onkoloji d\u00f6neminin temellerinin sa\u011flam at\u0131lmas\u0131n\u0131 destekliyor.<\/p>\n
Sonu\u00e7 olarak, IL13R\u03b12 biomarker olarak k\u00f6t\u00fc prognozun simgesi olmaktan \u00e7\u0131k\u0131p, hedefe y\u00f6nelik etkin m\u00fcdahalelerin merkezi unsuru haline geliyor. KLG-3\u2019\u00fcn sa\u011flad\u0131\u011f\u0131 bu f\u0131rsat, \u00f6zellikle tedavi se\u00e7enekleri k\u0131s\u0131tl\u0131, ya\u015fam\u0131 tehdit eden glioblastom ve melanom gibi agresif t\u00fcm\u00f6rlerde hastalar\u0131n gelece\u011fini ayd\u0131nlatacak. Bu \u00e7al\u0131\u015fma, onkolojide hassas tedavi ve g\u00f6r\u00fcnt\u00fclemenin gelece\u011finde b\u00fcy\u00fck bir mihenk ta\u015f\u0131 olacak.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: IL13R\u03b12 hedefli antikorlar\u0131n kat\u0131 t\u00fcm\u00f6rlerde immuno-PET g\u00f6r\u00fcnt\u00fcleme ve radyoimmunoterapi ama\u00e7l\u0131 geli\u015ftirilmesi ve de\u011ferlendirilmesi.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: IL13R\u03b12-Targeting Antibodies for Immuno-PET in Solid Malignancies<\/p>\n Haberin Yay\u0131n Tarihi<\/strong>: 17 Nisan 2025<\/p>\n Web References<\/strong>: https:\/\/doi.org\/10.2967\/jnumed.124.268762<\/p>\n Doi Referans<\/strong>: 10.2967\/jnumed.124.268762<\/p>\n Resim Credits<\/strong>: Leah Gajecki ve ekipleri, Memorial Sloan Kettering Cancer Center, Sander Tri-Institutional Therapeutics Discovery Institute, The University of Texas MD Anderson Cancer Center<\/p>\n Anahtar Kelimeler<\/strong>: Molek\u00fcler g\u00f6r\u00fcnt\u00fcleme, Molek\u00fcler hedefler, Kanser ara\u015ft\u0131rmas\u0131, glioblastom tedavi geli\u015fmeleri, IL13R\u03b12 kanser biyobelirteci, KLG-3 antikor \u00e7al\u0131\u015fmas\u0131, melanom hedefli tedaviler, molek\u00fcler g\u00f6r\u00fcnt\u00fcleme hassasiyeti, yeni radyoaktif i\u015faretli antikor, off-target toksisite azalt\u0131m\u0131, hassas onkoloji g\u00f6r\u00fcnt\u00fclemesi, preklinik antikor kan\u0131tlar\u0131, kat\u0131 t\u00fcm\u00f6r tan\u0131s\u0131, hedefe y\u00f6nelik radyoimmunoterapi, \u00fc\u00e7l\u00fc negatif meme kanseri ara\u015ft\u0131rmas\u0131<\/p>\n","protected":false},"excerpt":{"rendered":" Geli\u015fen onkoloji d\u00fcnyas\u0131nda, kanser tan\u0131 ve tedavisine y\u00f6nelik yeni nesil molek\u00fcler hedeflerin ke\u015ffi, hasta y\u00f6netiminde devrim niteli\u011finde ad\u0131mlar\u0131n at\u0131lmas\u0131n\u0131 sa\u011fl\u0131yor. Nisan 2025\u2019te Journal of Nuclear Medicine\u2019da yay\u0131mlanan \u00f6nc\u00fc bir \u00e7al\u0131\u015fma, agresif kat\u0131 t\u00fcm\u00f6rlerde belirgin \u015fekilde a\u015f\u0131r\u0131 eksprese edilen IL13R\u03b12 adl\u0131 antijen \u00fczerinde y\u00fcksek \u00f6zg\u00fcll\u00fc\u011fe sahip, radyoaktif i\u015faretlenmi\u015f yenilik\u00e7i bir antikor geli\u015ftirilerek bu alanda \u00e7\u0131\u011f\u0131r a\u00e7t\u0131….<\/p>\n","protected":false},"author":1,"featured_media":3140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[1422,1420,1421,1418,1419],"tmauthors":[],"class_list":{"0":"post-3139","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-agresif-kati-tumorlerde-hedefe-yonelik-antikor-tedavisi","9":"tag-il13r2-antijenine-ozgu-molekuler-onkoloji-terapileri","10":"tag-immuno-pet-goruntulemede-radyoizotoplu-antikor-uygulamalari","11":"tag-kati-tumorlerde-il13r2-hedefli-radyolabel-antikor-kullanimi","12":"tag-klg-3-radyoaktif-isaretli-antikor-ile-glioblastom-tedavisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Kati-Tumorlerde-Yeni-Radyolabel-Antikor-Kullanimi-1744987468.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3139"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3139\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3140"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3139"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}